
Haemonetics (NYSE:HAE) signed a 2-year exclusive supply deal with HemeXcel Purchasing Alliance LLC, providing blood collection devices to group purchasing organization HemeXcel’s 5 blood centers.
Altogether, HemeXcel’s sites collect, process, and distribute 4.8 million blood components every year, serving 1,400 hospitals in 29 states, according to a press release.
“Our commitments to [HemeXcel] are a continual stream of differentiating new products and best-in-class customer service," Haemonetics’ President & CEO Brian Concannon said prepared remarks. "The investments we’ve made over the past 2 years have resulted in a robust new product pipeline, positioning us well to bring meaningful differentiation and economical solutions to our whole blood customers."
The 2-year exclusive deal will not have an impact on Haemonetics’ fiscal 2014 revenue, the company announced during the J.P. Morgan Healthcare conference in San Francisco this week.